The thesis

argenx SE is a biotechnology company with 602.2% YoY revenue growth and 8994.0% gross margin. The company's conviction score is 33/100, indicating low conviction. Analyst consensus is BUY, but the DCF intrinsic value is -$5533, suggesting valuation concerns. The high revenue growth makes it an interesting setup despite the risk-off rotation in biotech.

Why now

The current macro context of increasing sanctions and market volatility makes biotech stocks like argenx SE more susceptible to risk-off rotation. With 602.2% revenue growth, argenx SE is well-positioned to withstand this volatility.

What to watch

Revenue growth trajectory and upcoming financial reports will be crucial in confirming or denying the thesis over the next quarter. Any significant changes in the macro context, such as further escalation of sanctions, will also impact the stock's performance.

Key risks

The high valuation multiple of 37.9x P/E and negative DCF intrinsic value of -$5533 pose significant valuation risks. Execution risk is also high given the company's reliance on innovative therapies for autoimmune diseases.

Theme exposure